Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peiminine is a steroidal alkaloid primarily isolated from the bulbs of various Fritillaria species, such as Fritillaria thunbergii and Fritillaria ussuriensis. It is a principal bioactive component in traditional Chinese medicine, where it is used for its expectorant and antitussive (cough suppressant) properties[1][4][5][10]. Peiminine displays a range of pharmacological effects, including strong anti-inflammatory, analgesic, and antitumor activities[4][10]. Mechanistically, it increases cyclic AMP (cAMP) and inhibits M2 muscarinic acetylcholine receptors (mAChRs); it may additionally modulate transient receptor potential channels TRPV1 and TRPA1[1]. In vitro and in vivo studies have demonstrated that peiminine suppresses signaling pathways such as PI3K–Akt, ERK1/2, MAPK, and NF-κB, resulting in the inhibition of cancer cell proliferation, induction of autophagy- and apoptosis-mediated cell death, and attenuation of inflammatory responses[1][3][4][6][9][10]. Preclinical research indicates peiminine's therapeutic potential against diseases like pulmonary fibrosis, osteoarthritis, glioblastoma, lung cancer, and osteosarcoma, but it is not approved as a pharmaceutical drug in any jurisdiction[4][6][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on peiminine.